Skip to main content
Premium Trial:

Request an Annual Quote

NRGene: Keith Blanks, Richard Calk

NRGene has hired Keith Blanks as chief commercial officer and Richard Calk as chief strategy officer. Blanks previously was senior VP of sales and marketing at Calyxt, where he led the launch of one of the world's first gene-edited food products. Calk joins NRGene after serving as president and COO of Neogen. NRGene said that the two will help the Israeli company grow in North America.

The Scan

For Better Odds

Bloomberg reports that a child has been born following polygenic risk score screening as an embryo.

Booster Decision Expected

The New York Times reports the US Food and Drug Administration is expected to authorize a booster dose of the Pfizer-BioNTech SARS-CoV-2 vaccine this week for individuals over 65 or at high risk.

Snipping HIV Out

The Philadelphia Inquirer reports Temple University researchers are to test a gene-editing approach for treating HIV.

PLOS Papers on Cancer Risk Scores, Typhoid Fever in Colombia, Streptococcus Protection

In PLOS this week: application of cancer polygenic risk scores across ancestries, genetic diversity of typhoid fever-causing Salmonella, and more.